{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_15788", "batch_size": 200, "batch_pos": 173, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain a high-potency verb, potent metaphor, or intensifier + harm noun.", "method": "llm_batch", "batch_id": "batch_2_14828", "batch_size": 200, "batch_pos": 140, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment describes a planned action ('will be used to complete'), not realised impact.", "method": "llm_batch", "batch_id": "batch_3_19408", "batch_size": 200, "batch_pos": 82, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment is a statement, not a question.", "method": "llm_batch", "batch_id": "batch_4_20584", "batch_size": 200, "batch_pos": 76, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "Lacks explicit calming language or keywords.", "method": "llm_batch", "batch_id": "batch_5_19136", "batch_size": 200, "batch_pos": 71, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_18748", "batch_size": 200, "batch_pos": 22, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_19140", "batch_size": 200, "batch_pos": 11, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "Describes preparedness ('negotiating with Pfizer for an mRNA vaccine') without calming keywords.", "method": "llm_batch", "batch_id": "batch_8_14172", "batch_size": 200, "batch_pos": 11, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
